SEO Article Directory Colorado: September 2016

Friday, September 30, 2016

Xanax XR

XANAX XR (alprazolam - tablet, extended release; oral)

Manufacturer: PHARMACIA AND UPJOHN

Approval date: January 17, 2003

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[RLD]^[AB]

Has a generic version of Xanax XR been approved?

Yes. The following products are equivalent to Xanax XR:

alprazolam tablet, extended release; oral

Manufacturer: ACTAVIS ELIZABETH

Approval date: February 13, 2007

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: AMNEAL PHARMS NY

Approval date: May 30, 2008

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: ANCHEN PHARMS

Approval date: September 29, 2011

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: APOTEX INC

Approval date: November 12, 2008

Strength(s): 0.5MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: AUROBINDO PHARMA USA

Approval date: June 7, 2011

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: BARR

Approval date: July 31, 2006

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: COREPHARMA

Approval date: January 31, 2007

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: IMPAX LABS

Approval date: May 24, 2007

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: MYLAN

Approval date: January 26, 2006

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: SANDOZ

Approval date: June 30, 2006

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: February 28, 2007

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: VINTAGE

Approval date: October 15, 2007

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: WATSON LABS FLORIDA

Approval date: May 13, 2010

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: October 17, 2008

Strength(s): 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB], 3MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xanax XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Xanax XR.

Has a generic version of Janumet been approved?

No. There is currently no therapeutically equivalent version of Janumet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Janumet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Patent 6,303,661
Issued: October 16, 2001
Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
Assignee(s): Probiodrug
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
Patent expiration dates:
- April 24, 2017
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Patent 6,699,871
Issued: March 2, 2004
Inventor(s): Scott D.; Edmondson & Michael H.; Fisher & Dooseop; Kim & Malcolm; Maccoss & Emma R.; Parmee & Ann E.; Weber & Jinyou; Xu
Assignee(s): Merck & Co., Inc.
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Patent expiration dates:
- July 26, 2022
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product

Method of regulating glucose metabolism, and reagents related thereto
Patent 6,890,898
Issued: May 10, 2005
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
1149336 Ontario Inc.
New England Medical Center Hospitals, Inc.
The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN

Method of regulating glucose metabolism, and reagents related thereto
Patent 7,078,381
Issued: July 18, 2006
Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
Assignee(s): Trustees of Tufts College
The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
Patent expiration dates:
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
- February 2, 2019
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST

Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Patent 7,125,873
Issued: October 24, 2006
Inventor(s): Edmondson; Scott D & Fisher; Michael H. & Kim; Dooseop & Maccoss; Malcolm & Parmee; Emma R. & Weber; Ann E & Xu; Jinyou
Assignee(s): Merck & Co., Inc.
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Patent expiration dates:
- July 26, 2022
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
  ✓
  Drug product
- July 26, 2022
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
  ✓
  Drug product
- July 26, 2022
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
  ✓
  Drug product

Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Patent 7,326,708
Issued: February 5, 2008
Inventor(s): Cypes; Stephen Howard & Chen; Alex Minhua & Ferlita; Russell R. & Hansen; Karl & Lee; Ivan & Vydra; Vicky K. & Wenslow, Jr.; Robert M.
Assignee(s): Merck & Co., Inc.
The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.
Patent expiration dates:
- April 11, 2026
  ✓
  Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- October 12, 2010 - DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
- October 12, 2010 - RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
- October 16, 2011 - NEW CHEMICAL ENTITY

Has a generic version of Nordette-28 been approved?

Yes. The following products are equivalent to Nordette-28:

ALTAVERA (ethinyl estradiol; levonorgestrel tablet; oral-28)

Manufacturer: SANDOZ

Approval date: August 3, 2010

Strength(s): 0.03MG;0.15MG ^[AB]

LEVORA 0.15/30-28 (ethinyl estradiol; levonorgestrel tablet; oral-28)

Manufacturer: WATSON LABS

Approval date: December 13, 1993

Strength(s): 0.03MG;0.15MG ^[AB]

PORTIA-28 (ethinyl estradiol; levonorgestrel tablet; oral-28)

Manufacturer: BARR

Approval date: May 23, 2002

Strength(s): 0.03MG;0.15MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nordette-28. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Nordette-28.

Has a generic version of Propecia been approved?

A generic version of Propecia has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Propecia and have been approved by the FDA:

finasteride tablet; oral

Manufacturer: DR REDDYS LABS INC

Approval date: July 28, 2006

Strength(s): 1MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Propecia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method of treating androgenic alopecia with 5-.alpha. reductase inhibitors
Patent 5,547,957
Issued: August 20, 1996
Inventor(s): Gormley; Glenn J. & Kaufman; Keith D. & Stoner; Elizabeth & Waldstreicher; Joanne
Assignee(s): Merck & Co., Inc.
The instant invention involves a method of treating and/or reversing androgenic alopecia and promoting hair growth, and methods of treating acne vulgaris, seborrhea, and female hirsutism, by administering to a patient in need of such treatment a 5.alpha.-reductase 2 inhibitor, such as finasteride, in a dosage amount under 5 mgs/day.
Patent expiration dates:
- October 15, 2013
  ✓
  Patent use: TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY

Methods of treating androgenic alopecia with finasteride [17.beta.-N-mono-substituted-carbamoyl-4-aza-5-.alpha.-androst-1-en-ones]
Patent 5,571,817
Issued: November 5, 1996
Inventor(s): Rasmusson; Gary H. & Reynolds; Glenn F.
Assignee(s): Merck & Co., Inc.
17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R.sup.1 is selected from hydrogen, methyl and ethyl and R.sup.2 is a branched chain alkyl of from 3-12 carbons, and R', R", R'" are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.
Patent expiration dates:
- November 5, 2013
  ✓
  Patent use: TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE

Finasteride processes
Patent 5,886,184
Issued: March 23, 1999
Inventor(s): Dolling; Ulf H. & McCauley; James A. & Varsolona; Richard J.
Assignee(s): Merck & Co., Inc.
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17.beta.-carboalkoxy-4-aza-5.alpha.-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the ester, formed from t-butyl amine and an aliphatic/aryl magnesium halide at ambient temperature in an inert organic solvent under an inert atmosphere followed by heating and recovering the product finasteride. Also disclosed are two polymorphic crystalline Forms I and II of finasteride, and methods of their production.
Patent expiration dates:
- November 19, 2012

Has a generic version of Beta-Val been approved?

Yes. The following products are equivalent to Beta-Val:

DERMABET (betamethasone valerate cream; topical)

Manufacturer: TARO

Approval date: January 6, 1988

Strength(s): EQ 0.1% BASE ^[AB]

VALNAC (betamethasone valerate cream; topical)

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: October 10, 1984

Strength(s): EQ 0.1% BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Beta-Val. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Beta-Val.

Has a generic version of Bactroban been approved?

A generic version of Bactroban has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Bactroban and have been approved by the FDA:

mupirocin ointment; topical

Manufacturer: FOUGERA PHARMS

Approval date: November 30, 2005

Strength(s): 2% ^[AB]

Manufacturer: GLENMARK PHARMS

Approval date: June 8, 2011

Strength(s): 2% ^[AB]

Manufacturer: PERRIGO NEW YORK

Approval date: November 7, 2003

Strength(s): 2% ^[AB]

Manufacturer: TARO

Approval date: September 23, 2005

Strength(s): 2% ^[AB]

Manufacturer: TEVA

Approval date: November 7, 2003

Strength(s): 2% ^[AB]

Note: No generic formulation of the following products are available.

mupirocin calcium - cream; topical

mupirocin calcium - ointment; nasal

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bactroban. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation
Patent 6,025,389
Issued: February 15, 2000
Inventor(s): Zimmerman; Harvey Lee
Assignee(s): SmithKline Beecham Corporation
The invention is directed to a pharmaceutical composition comprising a cream base which comprises mupiricin dihydrate, a mineral oil, one or more fatty alcohols or fatty esters, a polyoxyethylene ether or ester surfactant, xanthan gum, water and a method for treating a bacterial infection using said composition.
Patent expiration dates:
- October 20, 2014
  ✓
  Patent use: TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
  ✓
  Drug product

Has a generic version of Xalkori been approved?

No. There is currently no therapeutically equivalent version of Xalkori available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xalkori. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Aminoheteroaryl compounds as protein kinase inhibitors
Patent 7,230,098
Issued: June 12, 2007
Inventor(s): Cui; Jingrong Jean & Bhumralkar; Dilip & Botrous; Iriny & Chu; Ji Yu & Funk; Lee A. & Hanau; Cathleen Elizabeth & Harris; G. Davis & Jia; Lei & Johnson; Joanne & Kolodziej; Stephen A. & Kung; Pei-Pei & Li; Xiaoyuan (Sharon) & Lin; Jason (Qishen) & Meng; Jerry Jialun & Nambu; Mitchel
Assignee(s): Sugen, Inc.
Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET
Patent expiration dates:
- March 1, 2025
  ✓
  Drug substance

Method of treating abnormal cell growth
Patent 7,825,137
Issued: November 2, 2010
Inventor(s): Christensen; James Gail & Zou; Yahong
Assignee(s): Pfizer Inc.
The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.
Patent expiration dates:
- May 12, 2027
  ✓
  Patent use: TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)

Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Patent 7,858,643
Issued: December 28, 2010
Inventor(s): Cui; Jingrong Jean & Funk; Lee Andrew & Jia; Lei & Kung; Pei-Pei & Meng; Jerry Jialun & Nambu; Mitchell David & Pairish; Mason Alan & Shen; Hong & Tran-Dube; Michelle
Assignee(s): Agouron Pharmaceuticals, Inc.
Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
Patent expiration dates:
- October 8, 2029
  ✓
  Drug substance
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- August 26, 2016 - NEW CHEMICAL ENTITY
- August 26, 2018 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Baraclude been approved?

No. There is currently no therapeutically equivalent version of Baraclude available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Baraclude. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines
Patent 5,206,244
Issued: April 27, 1993
Inventor(s): Zahler; Robert & Slusarchyk; William A.
Assignee(s): E. R. Squibb & Sons, Inc.
Antiviral activity is exhibited by compounds having the formula ##STR1## and its pharmaceutically acceptable salts.
Patent expiration dates:
- February 21, 2015
  ✓
  Drug substance

Related Exclusivities

Exclusivity expiration dates:
- October 15, 2013 - DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE

Has a generic version of NuvaRing been approved?

No. There is currently no therapeutically equivalent version of NuvaRing available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of NuvaRing. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Drug delivery system for two or more active substances
Patent 5,989,581
Issued: November 23, 1999
Inventor(s): Groenewegen; Rudolf Johannes Joseph
Assignee(s): Akzo Nobel N.V.
The present invention is dealing with a drug delivery system, preferably in a ring-shaped form suitable for vaginal administration, for the simultaneous release of a progestogenic steroid compound and an estrogenic steroid compound in a fixed physiological ratio over a prolonged period of time. The drug delivery system comprises at least one compartment comprising a thermoplastic polymer core containing the mixture of the progestogenic and estrogenic compounds and a thermoplastic polymer skin, the progestogenic compound being initially dissolved in the polymer core material in a relatively low degree of supersaturation.
Patent expiration dates:
- April 8, 2018

Has a generic version of Xolegel been approved?

No. There is currently no therapeutically equivalent version of Xolegel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xolegel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Anhydrous topical skin preparations
Patent 7,179,475
Issued: February 20, 2007
Inventor(s): Burnett; Katherine M. & Kurtz; Ellen S.
Assignee(s): Johnson & Johnson Consumer Companies, Inc.
The present invention provides anhydrous compositions for topical delivery of a medicament comprising (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol, or any combination of any of the foregoing; and (C) an anhydrous vehicle. In an alternate embodiment, the present invention provides anhydrous compositions for topical delivery of a medicament which comprise (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol or any combination of any of the foregoing; (C) an anhydrous vehicle; and (D) a medicament. Also provided are methods for topically delivering a medicament to an animal, such as a mammal or a human patient, in need of the medicament by topically administering to the animal the compositions of the present invention.
Patent expiration dates:
- December 4, 2018
  ✓
  Patent use: TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
  ✓
  Drug product

Has a generic version of Xyzal been approved?

A generic version of Xyzal has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Xyzal and have been approved by the FDA:

levocetirizine dihydrochloride solution; oral

Manufacturer: SYNTHON PHARMS

Approval date: November 7, 2011

Strength(s): 2.5MG/5ML ^[AA]

levocetirizine dihydrochloride tablet; oral

Manufacturer: DR REDDYS LABS LTD

Approval date: February 24, 2011

Strength(s): 5MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: February 24, 2011

Strength(s): 5MG ^[AB]

Manufacturer: SYNTHON PHARMS

Approval date: November 26, 2010

Strength(s): 5MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: August 22, 2011

Strength(s): 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xyzal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Methods for treating allergic disorders using optically pure (-) cetirizine
Patent 5,698,558
Issued: December 16, 1997
Inventor(s): Gray; Nancy M.
Assignee(s): Sepracor, Inc.
Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.
Patent expiration dates:
- September 24, 2012
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- September 24, 2012
  ✓
  Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
- March 24, 2013
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- November 25, 2010 - PEDIATRIC EXCLUSIVITY
- August 21, 2012 - NEW PATIENT POPULATION
- February 21, 2013 - PEDIATRIC EXCLUSIVITY

Has a generic version of Xyrem been approved?

No. There is currently no therapeutically equivalent version of Xyrem available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xyrem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Patent 6,780,889
Issued: August 24, 2004
Inventor(s): Harry; Cook & Martha; Hamilton & Douglas; Danielson & Colette; Goderstad & Dayton; Reardan
Assignee(s): Orphan Medical, Inc.
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
Patent expiration dates:
- July 4, 2020
  ✓
  Drug product

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Patent 7,262,219
Issued: August 28, 2007
Inventor(s): Cook; Harry & Hamilton; Martha & Danielson; Douglas & Goderstad; Colette & Reardan; Dayton
Assignee(s): Orphan Medical, Inc.
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
Patent expiration dates:
- July 4, 2020
  ✓
  Drug product

Sensitive drug distribution system and method
Patent 7,668,730
Issued: February 23, 2010
Inventor(s): Reardan; Dayton T. & Engle; Patti & Gagne; Bob
Assignee(s): JPI Commercial, LLC.
A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.
Patent expiration dates:
- June 16, 2024
  ✓
  Patent use: METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

Sensitive drug distribution system and method
Patent 7,765,106
Issued: July 27, 2010
Inventor(s): Reardan; Dayton T. & Engel; Patti A. & Gagne; Bob
Assignee(s): JPI Commercial, LLC
A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.
Patent expiration dates:
- June 16, 2024
  ✓
  Patent use: A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

Sensitive drug distribution system and method
Patent 7,765,107
Issued: July 27, 2010
Inventor(s): Reardan; Dayton T. & Engel; Patti A. & Gagne; Bob
Assignee(s): JPI Commercial, LLC.
A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.
Patent expiration dates:
- June 16, 2024
  ✓
  Patent use: A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Patent 7,851,506
Issued: December 14, 2010
Inventor(s): Cook; Harry & Hamilton; Martha & Danielson; Douglas & Goderstad; Colette & Reardan; Dayton
Assignee(s): Jazz Pharmaceuticals, Inc.
Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
Patent expiration dates:
- December 22, 2019
  ✓
  Patent use: METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
- December 22, 2019
  ✓
  Patent use: METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

Sensitive drug distribution system and method
Patent 7,895,059
Issued: February 22, 2011
Inventor(s): Reardan; Dayton T. & Engel; Patti A. & Gagne; Bob
Assignee(s): Jazz Pharmaceuticals, Inc.
A drug distribution system and method utilizes a central pharmacy and database to track all prescriptions for a sensitive drug. Information is kept in the database regarding all physicians allowed to prescribe the sensitive drug, and all patients receiving the drug. Abuses are identified by monitoring data in the database for prescription patterns by physicians and prescriptions obtained by patients. Further verification is made that the physician is eligible to prescribe the drug by consulting a separate database, and optionally whether any actions are taken against the physician. Multiple controls beyond those for normal drugs are imposed on the distribution depending on the sensitivity of the drug.
Patent expiration dates:
- December 17, 2022
  ✓
  Patent use: METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

Related Exclusivities

Exclusivity expiration dates:
- November 18, 2012 - ORPHAN DRUG EXCLUSIVITY

Has a generic version of Xanax been approved?

Yes. The following products are equivalent to Xanax:

alprazolam tablet; oral

Manufacturer: ACTAVIS ELIZABETH

Approval date: October 31, 1993

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: ALPHAPHARM

Approval date: October 19, 1993

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB]

Manufacturer: ALPHAPHARM

Approval date: May 7, 1997

Strength(s): 2MG ^[AB]

Manufacturer: APOTEX INC

Approval date: January 19, 2007

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: BOCA PHARMA

Approval date: September 17, 2010

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: DAVA INTL INC

Approval date: October 19, 1993

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: MYLAN

Approval date: January 27, 1994

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: SANDOZ

Approval date: December 29, 1995

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB]

Manufacturer: SANDOZ

Approval date: March 25, 1998

Strength(s): 2MG ^[AB]

Manufacturer: SUN PHARMA GLOBAL

Approval date: June 17, 2010

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB], 2MG ^[AB]

Manufacturer: VINTAGE

Approval date: September 25, 2008

Strength(s): 0.25MG ^[AB], 0.5MG ^[AB], 1MG ^[AB]

Manufacturer: VINTAGE

Approval date: December 12, 2008

Strength(s): 2MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xanax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Xanax.

Has a generic version of Xopenex HFA been approved?

No. There is currently no therapeutically equivalent version of Xopenex HFA available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xopenex HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method for treating asthma using optically pure (R)-albuterol
Patent 5,362,755
Issued: November 8, 1994
Inventor(s): Barberich; Timothy J. & Young; James W.
Assignee(s): Sepracor, Inc.
The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with chronic administration of racemic albuterol.
Patent expiration dates:
- March 25, 2013
  ✓
  Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

Method for treating asthma using optically pure R(-) albuterol
Patent 5,547,994
Issued: August 20, 1996
Inventor(s): Barberich; Timothy J. & Young; James W.
Assignee(s): Sepracor, Inc.
The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
Patent expiration dates:
- August 20, 2013
  ✓
  Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS

Medicinal aerosol formulations
Patent 5,605,674
Issued: February 25, 1997
Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
Assignee(s): Riker Laboratories, Inc.
A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
Patent expiration dates:
- February 25, 2014
  ✓
  Drug product

Seals for use in an aerosol delivery device
Patent 5,836,299
Issued: November 17, 1998
Inventor(s): Kwon; Oh-Seung
Assignee(s): Minnesota Mining & Manufacturing Co.
A device for delivering an aerosol, comprising: a casing member, a valve stem, and a diaphragm. The diaphragm is made of an ethylene-propylene-diene rubber ("EPDM") and is stable to dimensional change when exposed to 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoroethane.
Patent expiration dates:
- November 17, 2015
  ✓
  Drug product

Levalbuterol salt
Patent 7,256,310
Issued: August 14, 2007
Inventor(s): McGlynn; Paul & Bakale; Roger & Sturge; Craig
Assignee(s): Sepracor Inc.
Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
Patent expiration dates:
- October 8, 2024
  ✓
  Patent use: TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
  ✓
  Drug substance
  ✓
  Drug product

Has a generic version of Xarelto been approved?

No. There is currently no therapeutically equivalent version of Xarelto available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xarelto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Substituted oxazolidinones and their use in the field of blood coagulation
Patent 7,157,456
Issued: January 2, 2007
Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Röhrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
Assignee(s): Bayer HealthCare AG
The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Patent expiration dates:
- February 8, 2021
  ✓
  Drug substance
  ✓
  Drug product

Substituted oxazolidinones and their use in the field of blood coagulation
Patent 7,585,860
Issued: September 8, 2009
Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
Assignee(s): Bayer Schering Pharma Aktiengesellschaft
The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Patent expiration dates:
- December 11, 2020
  ✓
  Drug substance

Substituted oxazolidinones and their use in the field of blood coagulation
Patent 7,592,339
Issued: September 22, 2009
Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
Assignee(s): Bayer Schering Pharma Aktiengesellschaft
The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Patent expiration dates:
- December 11, 2020
  ✓
  Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- December 11, 2020
  ✓
  Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM

Related Exclusivities

Exclusivity expiration dates:
- November 4, 2014 - REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
- July 1, 2016 - NEW CHEMICAL ENTITY

Has a generic version of Welchol been approved?

No. There is currently no therapeutically equivalent version of Welchol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Welchol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Amine polymer sequestrant and method of cholesterol depletion
Patent 5,607,669
Issued: March 4, 1997
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen R.
Assignee(s): GelTex Pharmaceuticals, Inc.
An amine polymer includes first and second substituents bound to amines of the polymer. The first substituent includes a hydrophobic moiety. The second substituent includes a quaternary amine-containing moiety. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the amine polymer.
Patent expiration dates:
- June 10, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
- June 10, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
- December 10, 2014
  ✓
  Pediatric exclusivity

Method for removing bile salts from a patient with alkylated amine polymers
Patent 5,679,717
Issued: October 21, 1997
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): GelTex Pharmaceuticals, Inc.
A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of product produced by a process comprising alkylating one or more crosslinked amine polymers, salts or copolymers thereof with at least one alkylating agent. The reaction product is characterized in that: (i) at least some of the nitrogen atoms are unreacted with alkylating agent; and (ii) less than 10 mol% of the nitrogen atoms in the polymer react with the alkylating agent to form quaternary ammonium units.
Patent expiration dates:
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
- October 29, 2014
  ✓
  Pediatric exclusivity

Alkylated amine polymers
Patent 5,693,675
Issued: December 2, 1997
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): GelTex Pharmaceuticals Inc.
The invention relates to alkylated amine polymers and a method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of product produced by a process comprising alkylating one or more crosslinked amine polymers, salts or copolymers thereof with at least one alkylating agent. The reaction product is characterized in that: (i) at least some of the nitrogen atoms are unreacted with alkylating agent; and (ii) less than 10 mol % of the nitrogen atoms in the polymer react with the alkylating agent to form quaternary ammonium units.
Patent expiration dates:
- December 2, 2014
- December 2, 2014
  ✓
  Drug substance
- June 2, 2015
  ✓
  Pediatric exclusivity

Process for removing bile salts from a patient and alkylated compositions therefor
Patent 5,917,007
Issued: June 29, 1999
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): GelTex Pharmaceuticals, Inc.
The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer comprises the reaction product of polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent and a crosslinking agent.
Patent expiration dates:
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
  ✓
  Drug substance
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
  ✓
  Drug substance
- October 29, 2014
  ✓
  Pediatric exclusivity

Amine polymer sequestrant and method of cholesterol depletion
Patent 5,919,832
Issued: July 6, 1999
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): Geltex Pharmaceuticals Inc.
An amine polymer includes first and second substituents bound to amines of the polymer. The first substituent includes a hydrophobic moiety. The second substituent includes a quaternary amine-containing moiety. A method for binding bile salts of bile acids in a mammal includes orally administering to the mammal a therapeutically-effective amount of the amine polymer.
Patent expiration dates:
- June 10, 2014
- April 29, 2014
  ✓
  Drug substance
- December 10, 2014
  ✓
  Pediatric exclusivity
- October 29, 2014
  ✓
  Pediatric exclusivity

Process for removing bile salts from a patient and alkylated compositions therefor
Patent 6,066,678
Issued: May 23, 2000
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): GelTex Pharmaceuticals, Inc.
The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer comprises the reaction product of polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent and a crosslinking agent.
Patent expiration dates:
- June 10, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT
  ✓
  Drug substance
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
  ✓
  Drug substance
- December 10, 2014
  ✓
  Pediatric exclusivity
- October 29, 2014
  ✓
  Pediatric exclusivity

Process for removing bile salts from a patient and alkylated compositions therefor
Patent 6,433,026
Issued: August 13, 2002
Inventor(s): W. Harry; Mandeville, III & Stephen Randall; Holmes-Farley
Assignee(s): GelTex Pharmaceuticals, Inc.
The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.
Patent expiration dates:
- June 10, 2014
- April 29, 2014
  ✓
  Drug substance
- December 10, 2014
  ✓
  Pediatric exclusivity
- October 29, 2014
  ✓
  Pediatric exclusivity

Process for removing bile salts from a patient and alkylated compositions therefor
Patent 6,784,254
Issued: August 31, 2004
Inventor(s): W. Harry; Mandeville, III & Stephen Randall; Holmes-Farley
Assignee(s): Genzyme Corporation
The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent.
Patent expiration dates:
- April 29, 2014
  ✓
  Drug substance
  ✓
  Drug product
- October 29, 2014
  ✓
  Pediatric exclusivity

Process for removing bile salts from a patient and alkylated compositions therefor
Patent 7,101,960
Issued: September 5, 2006
Inventor(s): Mandeville, III; W. Harry & Holmes-Farley; Stephen Randall
Assignee(s): Genzyme Corporation
The invention relates to a method for reducing serum cholesterol in a patient in need thereof and alkylated and crosslinked poly(allylamine) polymers useful in the method. The alkylated and crosslinked poly(allylamine) polymers are crosslinked with epichlorohydrin and comprise at least some n-decyl substituted nitrogen atoms and at least some hexyltrimethyl ammonium substituted nitrogen atoms.
Patent expiration dates:
- April 29, 2014
  ✓
  Patent use: USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
  ✓
  Drug substance
  ✓
  Drug product
- October 29, 2014
  ✓
  Pediatric exclusivity

Method for lowering serum glucose
Patent 7,229,613
Issued: June 12, 2007
Inventor(s): Burke; Steven K. & Donovan; Joanne M.
Assignee(s): Genzyme Corporation
A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula: and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.
Patent expiration dates:
- April 17, 2022
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
- April 17, 2022
  ✓
  Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
- October 17, 2022
  ✓
  Pediatric exclusivity

Related Exclusivities

Exclusivity expiration dates:
- January 18, 2011 - FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- July 18, 2011 - PEDIATRIC EXCLUSIVITY
- October 2, 2012 - REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
- April 2, 2013 - PEDIATRIC EXCLUSIVITY

Friday, September 30, 2016

XANAX XR (alprazolam - tablet, extended release; oral)

Has a generic version of Xanax XR been approved?

alprazolam tablet, extended release; oral

Related Patents

See also...

JANUMET (metformin hydrochloride; sitagliptin phosphate - tablet; oral)

Has a generic version of Janumet been approved?

Related Patents

Related Exclusivities

See also...

NORDETTE-28 (ethinyl estradiol; levonorgestrel - tablet; oral-28)

Has a generic version of Nordette-28 been approved?

ALTAVERA (ethinyl estradiol; levonorgestrel tablet; oral-28)

LEVORA 0.15/30-28 (ethinyl estradiol; levonorgestrel tablet; oral-28)

PORTIA-28 (ethinyl estradiol; levonorgestrel tablet; oral-28)

Related Patents

See also...

PROPECIA (finasteride - tablet; oral)

Has a generic version of Propecia been approved?

finasteride tablet; oral

Related Patents

See also...

BETA-VAL (betamethasone valerate - cream; topical)

Has a generic version of Beta-Val been approved?

DERMABET (betamethasone valerate cream; topical)

VALNAC (betamethasone valerate cream; topical)

Related Patents

See also...

BACTROBAN (mupirocin - ointment; topical)

BACTROBAN (mupirocin calcium - cream; topical)

BACTROBAN (mupirocin calcium - ointment; nasal)

Has a generic version of Bactroban been approved?

mupirocin ointment; topical

Related Patents

See also...

XALKORI (crizotinib - capsule; oral)

Has a generic version of Xalkori been approved?

Related Patents

Related Exclusivities

See also...

BARACLUDE (entecavir - solution; oral)

BARACLUDE (entecavir - tablet; oral)

Has a generic version of Baraclude been approved?

Related Patents

Related Exclusivities

See also...

NUVARING (ethinyl estradiol; etonogestrel - ring; vaginal)

Has a generic version of NuvaRing been approved?

Related Patents

See also...

XOLEGEL (ketoconazole - gel; topical)

Has a generic version of Xolegel been approved?

Related Patents

See also...

XYZAL (levocetirizine dihydrochloride - solution; oral)

XYZAL (levocetirizine dihydrochloride - tablet; oral)

Has a generic version of Xyzal been approved?

levocetirizine dihydrochloride solution; oral

levocetirizine dihydrochloride tablet; oral

Related Patents

Related Exclusivities

See also...

XYREM (sodium oxybate - solution; oral)

Has a generic version of Xyrem been approved?

Related Patents

Related Exclusivities

See also...

XANAX (alprazolam - tablet; oral)

Has a generic version of Xanax been approved?

alprazolam tablet; oral

Related Patents

See also...

XOPENEX HFA (levalbuterol tartrate - aerosol, metered; inhalation)

Has a generic version of Xopenex HFA been approved?

Related Patents

See also...

XARELTO (rivaroxaban - tablet; oral)

Has a generic version of Xarelto been approved?

Related Patents